The utility of Rna Diagnostics’ RDA™ (Rna Disruption Assay) test in assessing the effect of chemotherapy drugs has been further illustrated in research just published by Toronto biopharma company Armour Therapeutics. The study entitled “Relaxin antagonist AT-001 synergizes with docetaxel in androgen-independent prostate xenografts” was published in leading journal, Endocrine-Related Cancer. Read more